Skip to main content

Written Parliamentary Question: 24th January 2007 (II)


Q:To ask the Secretary of State for Health what estimate she has made of the effects on costs to the public purse of prescribing Simvastatin instead of Atorvastatin or other branded statins; and what the timetable is for Simvastatin to be prescribed instead of branded statins.

A:The NHS Institute for Innovation and Improvement recently published the "Better Care, Better Value" indicators for the second quarter of this financial year. The statins indicator shows that if every primary care trust (PCT) achieved levels of prescribing of lower cost statins similar to the top quarter of PCTs then £84.7 million could be released for patient care. There are no targets, but we expect PCTs and clinicians to be aware that they can help treat more patients by prescribing one of the lower cost statins where it is clinically appropriate. (Caroline Flint, Minister of State (Public Health), Department of Health)


Popular posts from this blog

Standards Board and Ken Livingstone

The link is to the case where Ken Livingstone appealed the decision of the Adjudication Panel for England. The Standards Board and associated Adjudication Panel have done a lot of damage to democracy in the UK. The courts are, however, bringing them into more sanity. The point about Ken Livingstone's case is that it was high profile and he also could afford to appeal. The Standard Board has a problem in that those subject to its enquiries face substantial costs that they cannot claim back. This is an issue that needs further work. In essence the Judge found that what he said brought him into disrepute, but not the office of Mayor. We do need the machinery of the SBE and APE to concentrate on things that matter rather than people being rude to each other.